LONG MINI-FUTURE - GENMAB | Real-time Boerse Frankfurt Warrants 07:53:07 2024-07-12 am EDT | ||
| 5.62 EUR | +12.40% |
|
| Current month | +15.21% | ||
| 1 month | -20.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 5.62 | +12.40% |
| 24-07-11 | 5 | +11.11% |
| 24-07-10 | 4.5 | -2.39% |
| 24-07-09 | 4.61 | +5.01% |
| 24-07-08 | 4.39 | -0.90% |
Real-time Boerse Frankfurt Warrants
Last update July 12, 2024 at 07:53 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VP1GA8 |
| ISIN | DE000VP1GA83 |
| Date issued | 2020-03-20 |
| Strike | 1,422 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.51 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 27.35 € |
|---|---|
| Lowest since issue | 1.09 € |
| Spread | 0.02 € |
| Spread % | 0.34% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,798
DKK
Average target price
2,446
DKK
Spread / Average Target
+36.06%
- Stock Market
- Certificates
- Certificat
